(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
----------
----------
INVESTEC CUTS ADMIRAL GROUP TO 'ADD' ('BUY') - PRICE TARGET 2400 PENCE
----------
UBS CUTS PEARSON TO 'NEUTRAL' ('BUY') - PRICE TARGET 600 (820) PENCE
----------
RBC RAISES AB FOODS PRICE TARGET TO 2850 (2800) PENCE - 'OUTPERFORM'
----------
BARCLAYS RAISES BRITISH AMERICAN TOBACCO PRICE TARGET TO 4200 (4000) PENCE - 'OVERWEIGHT'
----------
COMMERZBANK RAISES EASYJET PRICE TARGET TO 1600 (1450) PENCE - 'HOLD'
----------
GOLDMAN SACHS RAISES GLENCORE TO 'BUY' ('NEUTRAL') - PRICE TARGET 280 (250) PENCE
----------
GOLDMAN CUTS ANTOFAGASTA PRICE TARGET TO 890 (910) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES ANGLO AMERICAN PRICE TARGET TO 2210 (2120) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS BHP GROUP PRICE TARGET TO 1750 (1800) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES RELX TO 'BUY' ('NEUTRAL') - TARGET 2300 (1880) PENCE
----------
JEFFERIES CUTS NMC HEALTH PRICE TARGET TO 1300 (1925) PENCE - 'UNDERPERFORM'
----------
JEFFERIES CUTS SMITH & NEPHEW PRICE TARGET TO 2160 (2200) PENCE - 'BUY'
----------
JPMORGAN CUTS MONDI TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 1730 (2000) PENCE
----------
DEUTSCHE BANK CUTS VODAFONE PRICE TARGET TO 233 (240) PENCE - 'BUY'
----------
RBC RAISES STANDARD LIFE ABERDEEN PRICE TARGET TO 265 (250) PENCE - 'UNDERPERFORM'
----------
----------
GOLDMAN CUTS HUNTING PRICE TARGET TO 402 (420) PENCE - 'SELL'
----------
GOLDMAN RAISES JOHN WOOD PRICE TARGET TO 467 (431) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS PETROFAC PRICE TARGET TO 483 (508) PENCE - 'NEUTRAL'
----------
RBC RAISES LANCASHIRE PRICE TARGET TO 850 (800) PENCE - 'OUTPERFORM'
----------
RBC RAISES HISCOX PRICE TARGET TO 1475 (1350) PENCE - 'SECTOR PERFORM'
----------
RBC RAISES BEAZLEY PRICE TARGET TO 675 (600) PENCE - 'OUTPERFORM'
----------
BARCLAYS RAISES UDG HEALTHCARE PRICE TARGET TO 910 (830) PENCE - 'OVERWEIGHT'
----------
GOLDMAN RAISES KAZ MINERALS PRICE TARGET TO 540 (500) PENCE - 'NEUTRAL'
----------
JEFFERIES RAISES CONVATEC PRICE TARGET TO 250 (220) PENCE - 'BUY'
----------
JEFFERIES CUTS DECHRA PHARMACEUTICAL PRICE TARGET TO 2930 (3090) PENCE - 'HOLD'
----------
JEFFERIES RAISES MEDICLINIC INTERNATIONAL PRICE TARGET TO 482 (457) PENCE - 'BUY'
----------
JEFFERIES RAISES SOFTCAT PRICE TARGET TO 1440 (1300) PENCE - 'BUY'
----------
JEFFERIES RAISES AVAST PRICE TARGET TO 627 (453) PENCE - 'BUY'
----------
JEFFERIES CUTS ELEMENTIS PRICE TARGET TO 153 (190) PENCE - 'HOLD'
----------
OTHER MAIN MARKET AND AIM
----------
UBS CUTS CARD FACTORY TO 'NEUTRAL' ('BUY') - PRICE TARGET 100 (220) PENCE
----------
BERENBERG RAISES LEARNING TECHNOLOGIES PRICE TARGET TO 190 (180) PENCE - 'BUY'
----------
DEUTSCHE BANK CUTS FEVERTREE DRINKS PRICE TARGET TO 1650 (2200) PENCE - 'HOLD'
----------
RBC CUTS FEVERTREE DRINKS PRICE TARGET TO 1300 (2200) PENCE - 'SECTOR PERFORM'
----------
JEFFERIES CUTS FEVERTREE DRINKS PRICE TARGET TO 1500 (2300) PENCE - 'HOLD'
----------
JEFFERIES CUTS SPIRE HEALTHCARE TO 'UNDERPERFORM' ('HOLD') - TARGET 113 (106) PENCE
----------
JEFFERIES CUTS GB GROUP TO 'HOLD' ('BUY') - TARGET 770 PENCE
----------
Copyright 2020 Alliance News Limited. All Rights Reserved.


* Lawsuit comes after Trump endorsed AG's rival for governor


* Lawsuit comes after Trump endorsed AG's rival for governor


SANTIAGO, June 3 (Reuters) - Chile's embattled state copper giant Codelco named Jorge Gomez as its new CEO on Wednesday as the company continues to ...


NMC Health Focused On Giving "Additional Clarity" As Shares Suspended


LONDON MARKET OPEN: FTSE Drops 175 Points With WPP, Travel Stocks Down


(Sharecast News) - Shares in Gulf healthcare firm NMC were suspended from trading on Thursday after its chief executive was dismissed amid a growing a...


TOP NEWS: NMC Health Fires CEO Manghat Amid Financial Discrepancies


LONDON MARKET CLOSE: FTSE 100 Claws Back Losses As US Markets Rally


UK BROKER RATINGS SUMMARY: Jefferies Raises Rentokil Initial To Buy


PRESS: Shetty Turns To Financial Advisors Amid NMC, Finablr Confusion


NMC Health Continues To Seek Answers Over Investor Stakes